This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Colleoni, M. Articles by Viale, G. Search for Related Content PubMed PubMed Citation Articles by Colleoni, M. Articles by Viale, G. Social Bookmarking                            What's this?

Size of Breast Cancer Metastases in Axillary Lymph Nodes: Clinical Relevance of Minimal Lymph Node Involvement

From the Division of Medical Oncology, Department of Medicine, Unit of Quality Control, Division of Epidemiology and Biostatistics, Division of Pathology, and Division of Senology, European Institute of Oncology; and University of Milan School of Medicine, Milan, Italy

Address reprint requests to Marco Colleoni, MD, Division of Medical Oncology, Department of Medicine, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141, Milan, Italy; e-mail: marco.colleoni{at}ieo.it

BACKGROUND: Overt ipsilateral axillary lymph node metastases of breast cancer are the most significant prognostic indicators for women who have undergone surgery, yet the clinical relevance of minimal involvement (isolated tumor cells and micrometastases) of these nodes is uncertain.

PATIENTS AND METHODS: We evaluated biologic features, adjuvant treatment recommendations, and prognosis for 1,959 consecutive patients with pT1-3, pN0, minimal lymph node involvement (pN1mi or pN0i+), or pN1a (single positive node) and M0, who were operated on and counseled for medical therapy from April 1997 to December 2000.

RESULTS: Patients with pN1a and pN1mi/pN0i+, when compared with patients with pN0 disease, were more often prescribed anthracycline-containing chemotherapy (39.1% v 33.2% v 6.1%, respectively; P < .0001) and were less likely to receive endocrine therapy alone (9.8% v 19.4% v 41.9%, respectively; P < .0001). At the multivariate analysis, a statistically significant difference in disease-free survival (DFS) and in the risk of distant metastases was observed for patients with pN1a versus pN0 disease (hazard ratio [HR] = 2.04; 95% CI, 1.46 to 2.86; P < .0001 for DFS; HR = 2.32; 95% CI, 1.42 to 3.80; P = .0007 for distant metastases) and for patients with pN1mi/pN0i+ versus pN0 disease (HR = 1.58; 95% CI, 1.01 to 2.47; P = .047 for DFS; HR = 1.94; 95% CI, 1.04 to 3.64; P = .037 for distant metastases).

CONCLUSION: Even minimal involvement of a single axillary node in breast cancer significantly correlates with worse prognosis compared with no axillary node involvement. Further studies are required before widespread modification of clinical practice.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. S. Pugliese, J. D. Beatty, R. J. Tickman, K. H. Allison, M. K. Atwood, J. Szymonifka, Z. M. Arthurs, P. P. Huynh, and J. H. Dawson Impact and Outcomes of Routine Microstaging of Sentinel Lymph Nodes in Breast Cancer: Significance of the pN0(i+) and pN1mi Categories Ann. Surg. Oncol., January 1, 2009; 16(1): 113 - 120. [Abstract] [Full Text] [PDF]

				P. D. Gobardhan, S. G. Elias, E. V. E. Madsen, V. Bongers, H. J. M. Ruitenberg, C. I. Perre, and T. van Dalen Prognostic value of micrometastases in sentinel lymph nodes of patients with breast carcinoma: a cohort study Ann. Onc., January 1, 2009; 20(1): 41 - 48. [Abstract] [Full Text] [PDF]

				R. R. Turner, D. L. Weaver, G. Cserni, S. C. Lester, K. Hirsch, D. A. Elashoff, P. L. Fitzgibbons, G. Viale, G. Mazzarol, J. A. Ibarra, et al. Nodal Stage Classification for Breast Carcinoma: Improving Interobserver Reproducibility Through Standardized Histologic Criteria and Image-Based Training J. Clin. Oncol., January 10, 2008; 26(2): 258 - 263. [Abstract] [Full Text] [PDF]

				P. Querzoli, M. Pedriali, R. Rinaldi, A. R. Lombardi, E. Biganzoli, P. Boracchi, S. Ferretti, C. Frasson, C. Zanella, S. Ghisellini, et al. Axillary Lymph Node Nanometastases Are Prognostic Factors for Disease-Free Survival and Metastatic Relapse in Breast Cancer Patients. Clin. Cancer Res., November 15, 2006; 12(22): 6696 - 6701. [Abstract] [Full Text] [PDF]

				M. J. Bolster, P. Bult, R. F. M. Schapers, J. W. R. Meijer, L. J. A. Strobbe, C. L. H. van Berlo, J. H. G. Klinkenbijl, P. G. M. Peer, T. Wobbes, and V. C. G. Tjan-Heijnen Differences in Sentinel Lymph Node Pathology Protocols Lead to Differences in Surgical Strategy in Breast Cancer Patients Ann. Surg. Oncol., November 1, 2006; 13(11): 1466 - 1473. [Abstract] [Full Text] [PDF]

				G. Houvenaeghel, C. Nos, H. Mignotte, J. M. Classe, S. Giard, P. Rouanet, F. P. Lorca, J. Jacquemier, and V. J. Bardou Micrometastases in Sentinel Lymph Node in a Multicentric Study: Predictive Factors of Nonsentinel Lymph Node Involvement--Groupe Des Chirurgiens De La Federation Des Centres De Lutte Contre Le Cancer J. Clin. Oncol., April 20, 2006; 24(12): 1814 - 1822. [Abstract] [Full Text] [PDF]

				N. E. Davidson, M. Morrow, D. B. Kopans, and F. C. Koerner Case 35-2005 -- A 56-Year-Old Woman with Breast Cancer and Isolated Tumor Cells in a Sentinel Lymph Node N. Engl. J. Med., November 17, 2005; 353(20): 2177 - 2185. [Full Text] [PDF]

				A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, and and Panel Members Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005 Ann. Onc., October 1, 2005; 16(10): 1569 - 1583. [Abstract] [Full Text] [PDF]